MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar
Release Date: 05/09/2025
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
MPR Weekly Dose
COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari
info_outline
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
MPR Weekly Dose
COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari
info_outline
MPR Weekly Dose Podcast #247 — AAP Release Pediatric Immunization Schedule; Blood Pressure MGMT Guideline; Wegovy Approved for Noncirrhotic MASH; New Fibromyalgia Tx; Investigational Sickle Cell Tx Fails to Meet Endpoint
MPR Weekly Dose
The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint.
info_outline
MPR Weekly Dose Podcast #246 — Device Cleared for Sleep Apnea; Skysona Safety Update; Non-Cystic Fibrosis Bronchiectasis Tx; Animal-Derived Thyroid Meds Safety Update; Synagis Discontinued
MPR Weekly Dose
Nerve stimulation device cleared for sleep apnea; Skysona safety update; new non-cystic fibrosis bronchiectasis treatment; FDA cracks down on animal-derived thyroid meds; RSV therapy to be discontinued.
info_outline
MPR Weekly Dose Podcast #245 — Label Change for Opioids; Results From Weight-Loss Pill Trial; Ajovy Approved for Some Peds; Ixchiq Vaccine Restrictions Lifted; Modeyso Approved for Rare Brain Tumor
MPR Weekly Dose
Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor.
info_outline
MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib
MPR Weekly Dose
Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.
info_outline
MPR Weekly Dose Podcast #243 — Sarepta Pauses Elevidys Shipments; Advisory Committee Votes Against PTSD Tx; Rapiblyk Now Available; Pill for Sleep Apnea; JUUL Cigs Authorized
MPR Weekly Dose
Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization.
info_outline
MPR Weekly Dose #242 — New indication for Kerendia; investigational Tx shows promise for hypertension; Novolog biosimilar; trial results for hormone-free contraceptive; new prefilled Shringrix syringe
MPR Weekly Dose
New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe.
info_outline
MPR Weekly Dose Podcast #241 — RFK Jr Sued Over Vaccine Policy Changes; Hereditary Angioedema Tx Approved; New OTC Blood Pressure Monitor; Kisunla Dosing Regime; REMS removed for ERA meds
MPR Weekly Dose
Lawsuit filed against RFK Jr over vaccine policy changes; oral on-demand treatment approved for HAE; OTC cuffless blood pressure monitor gets greenlit; dosing schedule update for Alzheimer treatment; REMS requirement removed for endothelin receptor antagonist meds.
info_outline
MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting
MPR Weekly Dose
Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.
info_outlineA new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara.